201 related articles for article (PubMed ID: 28434274)
1. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
De Cicco S; Immediata V; Romualdi D; Policola C; Tropea A; Di Florio C; Tagliaferri V; Scarinci E; Della Casa S; Lanzone A; Apa R
Gynecol Endocrinol; 2017 Sep; 33(9):698-701. PubMed ID: 28434274
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
Fruzzetti F; Fidecicchi T; Palla G; Gambacciani M
Gynecol Endocrinol; 2020 Feb; 36(2):152-155. PubMed ID: 31317814
[TBL] [Abstract][Full Text] [Related]
4. HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
Cirillo F; Catellani C; Lazzeroni P; Sartori C; Tridenti G; Vezzani C; Fulghesu AM; Madeddu E; Amarri S; Street ME
Gynecol Endocrinol; 2020 Jul; 36(7):588-593. PubMed ID: 32054355
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Cappelli V; Di Sabatino A; Musacchio MC; De Leo V
Minerva Ginecol; 2013 Aug; 65(4):425-33. PubMed ID: 24051942
[TBL] [Abstract][Full Text] [Related]
6. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
[TBL] [Abstract][Full Text] [Related]
7. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
8. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Stracquadanio M; Ciotta L; Palumbo MA
Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
[TBL] [Abstract][Full Text] [Related]
9. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
10. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
11. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
12. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study.
Rago R; Marcucci I; Leto G; Caponecchia L; Salacone P; Bonanni P; Fiori C; Sorrenti G; Sebastianelli A
J Biol Regul Homeost Agents; 2015; 29(4):913-23. PubMed ID: 26753656
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
[TBL] [Abstract][Full Text] [Related]
14. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
16. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
Elter K; Imir G; Durmusoglu F
Hum Reprod; 2002 Jul; 17(7):1729-37. PubMed ID: 12093831
[TBL] [Abstract][Full Text] [Related]
17. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
18. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
[TBL] [Abstract][Full Text] [Related]
20. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
Tagliaferri V; Romualdi D; Immediata V; De Cicco S; Di Florio C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2017 May; 86(5):725-730. PubMed ID: 28092404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
